Kodiak Sciences
NASDAQ: KODPalo Alto, US · Delaware corporation
Kodiak Sciences develops biopharmaceutical therapies for chronic ophthalmic diseases, with a focus on patient outcomes and stakeholder impact in the healthcare system.
Founders & leadership
JB
John BorgesoninExecutive Vice President, Chief Financial Officer
Reported raises · per SEC filings
Form D private placements$34M disclosed across 1 round · 2015
▶$34MraisedMar 2016 · 13 investors · BiotechnologyRule 506(b)
▶$34MraisedMar 2016 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John BorgesonExecutive Officer
- Offering amount
- $34M
- Amount sold
- $34M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Kodiak Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Kodiak Sciences do?
- Kodiak Sciences develops biopharmaceutical therapies for chronic ophthalmic diseases, with a focus on patient outcomes and stakeholder impact in the healthcare system.
- How much funding has Kodiak Sciences raised?
- Kodiak Sciences has disclosed $34M raised across 1 round.
- Where is Kodiak Sciences headquartered?
- Kodiak Sciences is headquartered in Palo Alto, US.